We previously showed using AFM and immunofluorescence analysis that the more aggressive triple-negative breast cancer (TNBC) and HER2+ human breast cancer subtypes have more cells with activated β1 integrin and develop a stiffer invasive front21,22. This evidence concerns the gene ERBB2 and breast carcinoma.